Dilon Technologies

Preliminary tests have demonstrated that a new device may enable up to six times better contrast of tumors in the breast, while maintaining the same or better image quality and halving the radiation dose to patients.

Molecular breast imaging (MBI/BSGI) has been proven to be a highly sensitive imaging technique for the diagnosis of invasive lobular carcinoma (ILC), a position supported by a recent publication in the Journal of the American Medical Association Surgery. Physicians at the Legacy Cancer Institute in Portland, Oregon, reported a sensitivity of 88.9 percent for MBI/BSGI in diagnosing ILC, a difficult-to-diagnose breast cancer.

When a health insurance company denies a claim, most people complain to their friends and family and then accept it, arranging payment methods or even denying themselves a procedure that may save their life. However, one patient decided to fight back and challenge her insurance carrier.

Dilon Technologies Inc. announced that it acquired the assets of the Navigator gamma probe business from RMD Instruments Corp., manufacturer and marketer of intraoperative surgical probes and subsidiary of Dynasil Corporation of America.

ECRI Institute released a report listing three key questions and the answers concerning breast-specific gamma imaging (BSGI; sometimes referred to as molecular breast imaging or MBI). The technology uses a specially designed gamma camera system to image the uptake of a tracer that emits gamma radiation (most commonly 99mtechnetium-sestamibi [MIBI]). MIBI is preferentially taken up by cancer tissue, and thus BSGI can be used to image breast cancer for a variety of clinical indications. Unlike X-ray mammography, BSGI is not affected by the density of breast tissue, and therefore it may be particularly useful for screening and diagnosis of breast cancer in women with dense breast tissue.